Theriva Biologics stellt Phase-1-Studienergebnisse zu VCN-01 bei refraktärem Retinoblastom vor

Reuters

Feb 03

<a href="https://laohu8.com/S/TOVX">Theriva Biologics</a> stellt Phase-1-Studienergebnisse zu VCN-01 bei refraktärem Retinoblastom vor

Theriva Biologics Inc. hat die bevorstehende Präsentation von Daten aus einer Phase-1-Studie zur Sicherheit und Wirksamkeit von VCN-01 (zabilugene almadenorepvec) bei pädiatrischen Patienten mit refraktärem intraokulärem Retinoblastom angekündigt. Die Ergebnisse der Studie sowie präklinische Daten zur Kombination von VCN-01 mit Topotecan werden im Rahmen des 41. Asia-Pacific Academy of Ophthalmology (APAO) Kongresses am 7. Februar 2026 in Hongkong vorgestellt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646501-en) on February 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608306879"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608306879\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608306879?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608306879","market":"nz","top_or_hot":-1,"title":"Theriva Biologics stellt Phase-1-Studienergebnisse zu VCN-01 bei refraktärem Retinoblastom vor","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TOVX\">Theriva Biologics</a> stellt Phase-1-Studienergebnisse zu VCN-01 bei refraktärem Retinoblastom vor\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Theriva Biologics Inc. hat die bevorstehende Präsentation von Daten aus einer Phase-1-Studie zur Sicherheit und Wirksamkeit von VCN-01 (zabilugene almadenorepvec) bei pädiatrischen Patienten mit refraktärem intraokulärem Retinoblastom angekündigt. Die Ergebnisse der Studie sowie präklinische Daten zur Kombination von VCN-01 mit Topotecan werden im Rahmen des 41. Asia-Pacific Academy of Ophthalmology (APAO) Kongresses am 7. Februar 2026 in Hongkong vorgestellt.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646501-en) on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Theriva Biologics stellt Phase-1-Studienergebnisse zu VCN-01 bei refraktärem Retinoblastom vor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTheriva Biologics stellt Phase-1-Studienergebnisse zu VCN-01 bei refraktärem Retinoblastom vor\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-03 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TOVX\">Theriva Biologics</a> stellt Phase-1-Studienergebnisse zu VCN-01 bei refraktärem Retinoblastom vor\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Theriva Biologics Inc. hat die bevorstehende Präsentation von Daten aus einer Phase-1-Studie zur Sicherheit und Wirksamkeit von VCN-01 (zabilugene almadenorepvec) bei pädiatrischen Patienten mit refraktärem intraokulärem Retinoblastom angekündigt. Die Ergebnisse der Studie sowie präklinische Daten zur Kombination von VCN-01 mit Topotecan werden im Rahmen des 41. Asia-Pacific Academy of Ophthalmology (APAO) Kongresses am 7. Februar 2026 in Hongkong vorgestellt.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646501-en) on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014039.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL6KFhWG:1","article_id":"2608306879","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608306879","pubTimestamp":1770123677,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Theriva Biologics Inc. hat die bevorstehende Prsentation von Daten aus einer Phase-1-Studie zur Sicherheit und Wirksamkeit von VCN-01  bei pdiatrischen Patienten mit refraktrem intraokulrem Retinoblastom angekündigt. Die Ergebnisse der Studie sowie prklinische Daten zur Kombination von VCN-01 mit Topotecan werden im Rahmen des 41. Asia-Pacific Academy of Ophthalmology  Kongresses am 7. Februar 2026 in Hongkong vorgestellt.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 03, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","TOVX":"Theriva Biologics","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技"},"translate_title":"Theriva Biologics公布VCN-01治疗难治性视网膜母细胞瘤的1期研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TOVX":0.9,"NDAQ":0.9},"content_text":"Theriva Biologics stellt Phase-1-Studienergebnisse zu VCN-01 bei refraktärem Retinoblastom vor\n    \n\n        Theriva Biologics Inc. hat die bevorstehende Präsentation von Daten aus einer Phase-1-Studie zur Sicherheit und Wirksamkeit von VCN-01 (zabilugene almadenorepvec) bei pädiatrischen Patienten mit refraktärem intraokulärem Retinoblastom angekündigt. Die Ergebnisse der Studie sowie präklinische Daten zur Kombination von VCN-01 mit Topotecan werden im Rahmen des 41. Asia-Pacific Academy of Ophthalmology (APAO) Kongresses am 7. Februar 2026 in Hongkong vorgestellt.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646501-en) on February 03, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}